N/A N=132 Clinical Comparison of Two Daily Wear Frequent Replacement Silicone Hydrogel Soft Contact Lenses
Refractive Errors · Ametropia
Primary: Distance Visual Acuity (VA) (Part A) — -0.12; -0.12 logMAR
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=248 PRISM 2.0 in Diverse Living Contexts
Social Isolation in Older Adults
Primary: Change in Functional Health/Well-being as Measured by Modified SF-36, a Self-report Measure of Functional Health and Well-being. — 855; 865; 900; 870 units on a scale
N/A N=61 Dementia Risk and Dynamic Response to Exercise
Alzheimer Disease 2 Due to Apoe4 Isoform · Healthy Aging
Primary: Cerebral Blood Flow Area Under Curve — 715; 751 mL/100g tissue
N/A N=36 Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations
Refractive Errors
Primary: Average Percent Area of Corneal Staining — 2.93; 0.45; 6.06; 3.52 percentage of area
Phase 3 N=947 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20 — 17.58; 14.59 Months — p=0.0469
Phase 2 N=44 Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Drug-Related Serious Adverse Events (SAEs) — 0 Participants
N/A N=491 Urinary Retention After Laparoscopic Inguinal Hernia Repair: Comparing the Use of the Intraoperative Urinary Catheter
Inguinal Hernia
Primary: Number of Participants With Post Operative Urinary Retention — 23; 21 Participants
N/A N=70 Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease · Non-alcoholic Steatohepatitis
Primary: Percent Change in Hepatic Steatosis as Measured by Controlled Attenuation Parameter (CAP) Score — -13.0; 8.7 percent change
N/A N=5 Intragastric Balloon in Obese Adolescents With Comorbidities
Obesity
Primary: Number of Subjects Achieving Greater Than or Equal to 10% Total Body Weight Loss — 2 Participants
Phase 2 N=178 A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
RSV Infection
Primary: Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load — 134.70; 113.51; 624.30; 80.61 hours*log10 copies/milliliter (mL) — p=< 0.001
N/A N=20 Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
Bacteriuria
Primary: Total Bacteria Count Change From Baseline and After 24 Hours. — -62519; 57448 CFU/mL — p=0.6250
Phase 2 N=30 Convalescent Plasma for Patients With COVID-19
Coronavirus Infection · Coronavirus · COVID
Primary: Change in Respiratory Disease Severity — 251; 276 ratio
Phase 1 N=18 A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)
Tumors
Primary: Number of Participants Who Experienced One or More Adverse Events — 4; 6; 3; 6 Participants
Phase 3 N=228 Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
Atopic Dermatitis
Primary: Percentage of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2-points From Baseline to Week 16. — 22.1; 41.2 percentage of…
N/A N=2,655 Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
Venous Thromboembolism
Primary: Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall — 3.8 Percentage of VTE recurrence